All In Biotech

Drug Trial Radar · NCT02974153

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine

Last checked: Nov 20, 2026Latest source record: Jun 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,121 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,121

Actual

Start

Nov 2016

Primary completion

Nov 2017

Study completion Apr 2018

Sponsor

Lead sponsor
Alder Biopharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Nov 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.

Conditions

  • Migraine Disorders

Interventions

  • ALD403 (Eptinezumab)Biological

  • PlaceboBiological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Monthly Migraine DaysTime frame: Week 1-12

Locations

144 sites in 13 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Carlsbad, California

  • Research Site

    Oceanside, California

  • Research Site

    Orange, California

  • Research Site

    Oxnard, California

  • Research Site

    Palo Alto, California

  • Research Site

    Redlands, California

  • Research Site

    San Diego, California

  • Research Site

    Santa Monica, California

  • Research Site

    Torrance, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    New London, Connecticut

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    West Palm Beach, Florida

  • Research Site

    Winter Haven, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Decatur, Georgia

  • Research Site

    Champaign, Illinois

  • Research Site

    Chicago, Illinois

  • Research Site

    Chicago, Illinois

  • Research Site

    Anderson, Indiana

  • Research Site

    Des Moines, Iowa

  • Research Site

    Overland Park, Kansas

  • Research Site

    Prairie Village, Kansas

  • Research Site

    Wichita, Kansas

  • Research Site

    Marrero, Louisiana

  • Research Site

    Waldorf, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    North Attleboro, Massachusetts

  • Research Site

    Watertown, Massachusetts

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Flowood, Mississippi

  • Research Site

    City of Saint Peters, Missouri

Showing 40 of 144 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.